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Abstract
We report on electroencephalograph (EEG) and electromyograph (EMG) measurements 
concurrently with real-time changes in L-glutamate concentration. These data reveal a link 
between sleep state and extracellular neurotransmitter changes in a freely-moving (tethered) 
mouse. This study reveals, for the first time in mice, that the extracellular L-glutamate 
concentration in the pre-frontal cortex (PFC) increases during periods of extended wakefulness, 
decreases during extended sleep episodes and spikes during periods of REM sleep. Individual 
sleep epochs (10 s in duration) were scored as wake, slow-wave (SW) sleep or rapid eye 
movement (REM) sleep, and then correlated as a function of time with measured changes in L-
glutamate concentrations. The observed L-glutamate levels show a statistically significant increase 
of 0.86 ± 0.26 μM (p < 0.05) over 37 wake episodes recorded from all mice (n = 6). Over the 
course of 49 measured sleep periods longer than 15 min, L-glutamate concentrations decline by a 
similar amount (0.88 ± 0.37 μM, p < 0.08). The analysis of 163 individual REM sleep episodes 
greater than one min in length across all mice (n = 6) demonstrates a significant rise in L-
glutamate levels as compared to the 1 min preceding REM sleep onset (RM-ANOVA, DF = 20, F 
= 6.458, p < 0.001). The observed rapid changes in L-glutamate concentration during REM sleep 
last only between 1 and 3 min. The approach described can also be extended to other regions of 
the brain which are hypothesized to play a role in sleep. This study highlights the importance of 
obtaining simultaneous measurements of neurotransmitter levels in conjunction with sleep markers 
to help elucidate the underlying physiological and ultimately the genetic components of sleep.
Keywords
Glutamate biosensor; Electroencephalography; Electromyography; Mouse sleep studies; 
Continuous in vivo monitoring
*Corresponding authors. Tel.: +1 785 864 5152; fax: +1 785 864 5396 (G.S. Wilson), tel.: +1 785 832 8866 (P.A. Petillo). 
gwilson@ku.edu (G.S. Wilson), alchmist@pinnaclet.com (P.A. Petillo). 
HHS Public Access
Author manuscript
J Electroanal Chem (Lausanne). Author manuscript; available in PMC 2016 April 11.
Published in final edited form as:














Electrophysiological studies aimed at elucidating the role of sleep in mammals are nearly a 
century old, and yet the function of sleep remains an elusive mystery [1]. Discrimination of 
sleep state activity relies on the accurate determination of electroencephalograph (EEG) and 
electromyograph (EMG) signals from a freely moving animal. EEG recordings of the brain 
yield a wealth of information regarding neuronal activity, but are limited in that these 
measurements only report gross neuronal firing patterns. Understanding the underlying 
physiology driving these large-scale neuronal events requires techniques that can accurately 
monitor neurochemical release and uptake. Such techniques can target specific structures 
within the brain to complement electrophysiological studies and are now recognized as an 
important component to investigating the role of sleep [2].
The predominant approach for the accurate determination of sleep state requires 
simultaneous EEG recordings from cortical regions of the brain and concurrent 
measurement of muscle EMG activity [3]. EEG traces reflect microvolt potential differences 
between two independent electrodes implanted in the skull. Potential differences ranging in 
size from 50 to 200 μV arise as a result of changes in membrane potentials due to neuronal 
firing activity. The frequency of EEG signals also reflects neuronal activity. High frequency 
(>12 Hz) EEG indicates active, disparate neuronal activation typically associated with 
waking. High amplitude (>100 μV), low frequency (<5 Hz) EEG activity, such as that 
observed during slow-wave (SW) sleep, represents cortical neurons firing in a highly 
synchronized rhythm. EEG traces with an abundance of 5–8 Hz frequencies whose 
amplitudes are <100 μV typically characterize rapid eye movement (REM) sleep. EMG 
activity, measured by placing two independent electrodes in muscle, reflects the electrical 
potential arising from the neuronal activation associated with muscle contraction. High 
amplitude EMG reflects active movement while a tonic EMG signal indicates quiescence or 
sleep [4].
Although measurement of brain and muscle electrical activity can indicate sleep states, it 
provides no indication of neurochemistry function. A better understanding of sleep 
physiology requires simultaneous measurements of neurotransmitter activity alongside EEG 
recordings. L-Glutamate, the most abundant excitatory neurotransmitter in the brain, is 
believed to play an important, but as yet undefined role during sleep. Previous studies in rats 
have shown altered L-glutamate levels between sleep/wake states [5] and increased 
extracellular L-glutamate concentration in the prefrontal cortex region during REM sleep 
[6].
Quantifying neurotransmitter concentration as a function of time concurrently with sleep is 
non-trivial. Traditionally, this sampling is accomplished using microdialysis [7], or post-
mortem techniques such as immunohistochemistry [8] or autoradiography [9]. Each of these 
techniques can provide useful data, but all suffer from similar limitations including the 
inability to monitor neurotransmitters in real-time (e.g. a lack of temporal resolution), and 
perturbation of the nascent equilibrium of the space being monitored (local environment). 
For example, microdialysis provides sampling over hours or days, but is typically limited to 
a rate no faster than 1–5 min per sample [5,10]. During microdialysis, removal of the analyte 
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from the local environment perturbs the natural equilibrium and post-collection processing 
of samples is laborious. Post-mortem techniques suffer from the extreme limitation of 
yielding only a single usable time point per animal and the necessary step of sacrifice 
interferes with measurement of sleep [8b]. The use of non-invasive techniques, such as MRI 
concurrently with EEG recording, have also been attempted, but these techniques require 
that the animal remain immobilized throughout the sampling period [11].
The simultaneous measurement of EEG, EMG and L-glutamate biosensor recordings is 
well-suited for quantifying second-by-second changes in neurotransmitter release during 
sleep in a manner that does not perturb the equilibrium of the local environment [12]. 
Biosensors employ biological recognition elements, typically an enzyme, to produce an 
electroactive species that is then oxidized at the transducing element [12]. In the case of an 
L-glutamate biosensor, a Pt–Ir electrode polarized to 0.6 V is coated in a matrix containing 
the biological element L-glutamate oxidase. L-Glutamate in the extracellular space 
surrounding the biosensor is converted to hydrogen peroxide (H2O2) by L-glutamate 
oxidase. The enzymatically-produced H2O2 then diffuses through various membrane layers 
to the Pt–Ir surface where it is oxidized to produce a measureable amperometric current 
[15].
Recent studies highlight the effectiveness of combining EEG and EMG recordings coupled 
with simultaneous biosensor measurements in a rat model [5,6,13]. These studies report 
elevation in glutamatergic activity during wake [6] and significant rises in L-glutamate levels 
during REM sleep episodes [10]. Without exception, all of these studies have been 
conducted using rats as the model organism. Rats are advantageous for physiological studies 
due to their size, but the results of these studies are difficult to leverage into the underlying 
genetics. The mouse, by virtue of its use as a genetic model, is a far more powerful means to 
investigate sleep [14].
Herein, we report on the measurement of EEG and EMG concurrently with real-time 
changes in L-glutamate concentration. These data reveal a link between sleep state and 
extracellular neurotransmitter changes in a freely-moving (tethered) mouse. A smaller 
subject (mouse vs. rat) demands further miniaturization of the data acquisition system. The 
in vivo measurement of L-glutamate is particularly challenging because of its low basal 
levels (~10 μM) [16]. L-Glutamate biosensors used in this study address this issue by 
harnessing the innate efficiency, activity, and specificity of the biological recognition 
element (L-glutamate oxidase) to provide high sensitivity. The biosensors are necessarily 
selective, rejecting significant potential interferences such as L-ascorbate. This study reveals, 
for the first time in mice, that the extracellular L-glutamate concentration in the pre-frontal 
cortex increases during periods of extended wakefulness, decreases during extended sleep 
episodes and spikes during periods of REM sleep.
2. Experimental
2.1. Animals
Six young (12–16 wks) male wild-type C57Bl6 mice were obtained from Jackson 
Laboratories (Bar Harbor, ME) and housed under a 12 h light/12 h dark cycle (LD 12:12) for 
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at least 3 weeks prior to surgery. All mice remained on LD 12:12 throughout the experiment 
with food and water available ad lib. All animal procedures were approved by the University 
of Kansas Animal Care and Use Committee.
2.2. Surgery
Mice were anesthetized using ketamine (100 mg/kg)/xylazine (10 mg/kg) and surgically 
implanted with electrodes for EEG and EMG recording along with an indwelling cannula for 
later biosensor implantation (Fig. 1). One stainless steel screw with an attached wire (Part 
#8403, Pinnacle Technology, Inc., Lawrence, KS) was positioned in the frontal region (A/P: 
−1.0 mm, M/L −1.5 mm) and two screws with wires were positioned over the posterior brain 
(A/P: −3.0 mm, M/L ±1.5 mm). EMG activity was monitored using dual Pt–Ir electrodes, 
partially coated with Teflon (Part #10IR5T, MedWire Mt.Vernon, NY), inserted bilaterally 
into the neck/back region (nuchal) muscles. All electrode leads were connected to a pre-
manufactured headmount (Part #8402, Pinnacle Technology, Inc., Lawrence, KS) and sealed 
with dental acrylic resin. A cannula for biosensor insertion (ID ~400 μm) (Part #MD-2255, 
BASi, West Lafayette, IN) was implanted in the pre-frontal cortex (A/P: +1.94 mm, M/L 
−1.50 mm, D/V −0.5 mm). Accuracy of the sensor placement was confirmed through visual 
examination of brain tissue during post-mortem analysis.
2.3. Biosensor construction
Glutamate biosensors obtained from Pinnacle Technology, Inc. (Part #7004-Glutamate, 
Lawrence, KS) were constructed according to previously published methods [16]. Briefly, 
the working electrode is formed by a Teflon-coated Pt–Ir wire (90% Pt, 10% Ir, Medwire, 
Mount Vernon, NY). A silver wire (Medwire, Mount Vernon, NY) is wrapped concentrically 
around the Pt–Ir wire and charged by oxidation in a FeCl3 (0.3 M in 0.1 M aqueous HCl) 
solution forming the AgCl reference electrode. At the distal end of the working electrode, a 
1 mm section is exposed to form the sensing cavity.
To protect the electrode surface from endogenous electroactive species (i.e. ascorbic acid), a 
selective membrane is cast over the surface of the working electrode. Ascorbic acid, a very 
predominant interferent encountered in mammalian brains [16,17] can reach concentrations 
as high as 300 μM. Electroactive interferents are excluded by the presence of a semi-
permeable membrane that allows the diffusion of H2O2 while retarding larger and negatively 
charged compounds. Assessment of likely interferences has been previously published [16a]. 
Additionally, L-ascorbate oxidase (EC 1.10.3.3) is co-immobilized with L-glutamate oxidase 
(EC 1.4.3.11) in the sensing cavity to actively remove L-ascorbate from the local 
environment (Fig. 2). A head-piece and connector coupled with a guide cannula is used for 
support in in vivo implantation. All biosensors are calibrated in vitro prior to implantation 
and after explantation.
2.4. Biosensor measurements
In vivo use of biosensors for detection of L-glutamate has been previously described [5,16a]. 
In this study, the L-glutamate biosensor was inserted into the guide cannula to extend 1 mm 
into the brain tissue below the cannula tip. Experiments were initiated at the onset of the 
“lights-off” period which coincided with the insertion of the biosensor. Amperometric 
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biosensor readings were collected once a second over the entire course of the experiment 
(total of 24 h of data collection), the first 12 h of which constituted the run-in period for in 
vivo stabilization of the biosensor. The biosensor measures L-glutamate in the extracellular 
fluid (ECF) of the brain. All biosensors were explanted through the guide cannula following 
the end of the experiment and immediately (<10 min) post-calibrated in a 37 °C bath 
containing 100 mM PBS (pH 7.4) buffer solution. Titration of the biosensor response was 
accomplished by stepwise addition of L-glutamate (10 μM) at regular intervals as for the 
pre-calibration (Fig. 3). Amperometric changes in individual biosensor readings were used 
to calculate concentration changes in vivo.
It should be noted that it is difficult, if not impossible, to perform an in vivo calibration of a 
biosensor when implanted in the brain of a conscious, freely moving (tethered) animal. 
Instead, the biosensor must be calibrated in vitro (Fig. 3), yet the calibration must still reflect 
its in vivo sensitivity which is typically up to 60% less than its pre-implantation sensitivity 
[16a]. This loss of sensitivity is due to bio-fouling and tissue stabilization that occur during 
the run-in period when the biosensor is equilibrating with its environment. Following this 
period, the in vivo sensitivity and selectivity of the biosensor is stable for at least 24 h. In 
order to determine the in vivo sensitivity over this time period, the biosensor is explanted at 
the conclusion of the experiment and immediately calibrated in vitro. When performed 
quickly (moving the biosensor from ‘brain-to-beaker’) this ‘post-calibration’ provides an 
excellent estimation of the biosensor in vivo sensitivity [18]. It has also been previously 
demonstrated that a “sentinel” electrode, one containing no enzyme, shows no response 
during stimulated glutamate release in the hippocampus [16a].
By calibrating each biosensor after explantation, the recorded in vivo current can be 
transformed into meaningful changes in L-glutamate concentration even though 
implantation can result in a 50% loss of sensitivity. Thus, multiple biosensors implanted in 
multiple animals are now directly comparable. The effectiveness of the L-ascorbate oxidase 
and interference membranes is also assessed during post-calibration via a single 250 μM 
injection of L-ascorbic acid [16a]. There may be some degradation of selectivity with 
respect to L-ascorbate, which translates into a slowly rising baseline. This does not 
materially affect calibration.
2.5. EEG/EMG data collection
A pre-amplifier unit (Part #8406-SL, Pinnacle Technology, Inc., Lawrence, KS), rigidly 
attached to the mouse headmount, provided first stage amplification (100×) and initial high-
pass filtering (first-order 0.5 Hz for EEG and 10 Hz for EMG). The signals were then routed 
to an 8401 conditioning/acquisition system (Pinnacle Technology, Inc., Lawrence, KS) via a 
tether and low-torque commutator (Part #8408, Pinnacle Technology, Inc., Lawrence, KS). 
The 8401 amplifier/conditioning unit provided an additional 50× signal amplification, 
additional high-pass filtering, and an 8th order elliptic low pass filter (50 Hz EEG and 200 
Hz EMG). The signals were then sampled at 500 Hz, digitized using a 14 bit A/D converter 
and routed to a PC based acquisition and analysis software package via USB.
By nature, mice are nocturnal and their circadian rhythm is such that the majority of wake 
activity is seen during periods of “lights-off”. Sleep and specifically REM sleep are typically 
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observed during “lights-on” periods. EEG, EMG and biosensor signals were continuously 
collected for a 24 h period following biosensor insertion at the start of the “lights-off” 
period. The first 12 h of the experiment (“lights-off”) were dedicated to sensor run-in and 
establishment of a stable biosensor signal. During the next 12 h (“lights-on”), corresponding 
to the period with the highest amount of SW and REM sleep, EEG, EMG and L-glutamate 
biosensor data were collected for analysis.
2.6. Sleep/wake analysis
Continuous sections of recorded EEG and EMG data were broken into discrete periods 
(epochs) lasting 10 s. Each 10 s epoch was classified as wake, SW or REM sleep based on 
which type of waveform occupied >50% of that time (Fig. 4a). This particular choice of 
sampling window is an optimal tradeoff between having sufficient data to make an accurate 
state determination and providing a dataset that can be sufficiently manipulated by a human 
scorer. First-pass scoring was accomplished using a cluster scoring method based on visual 
clustering similar to that described by Benington et al. [19]. Cluster scoring helps define the 
transition epochs which are then scored as wake, SW sleep or REM sleep by human visual 
pattern recognition. Post-scoring data processing utilized the PAL-8200 analysis package 
(Pinnacle Technology, Inc. Lawrence, KS). Final sleep state determination of any epoch 
which was not clearly delineated by the cluster method was scored through visual 
examination.
Fig. 4a shows the EEG/EMG data from the three states, wake, SW and REM. An 
examination of the EMG signal clearly distinguishes the two sleep states from the wake 
state, where the movement of the mouse causes large changes in the observed EMG 
amplitudes and frequencies. The residual signal in the two sleep states is largely due to the 
measurement of heart beat. The EEG-1 and EEG-2 amplitudes measured in the same mouse 
are different, largely due to the dissimilar spatial orientation between the two electrodes and 
the EEG common electrode (Fig. 1b). Qualitatively, SW sleep is of a lower frequency than 
either the wake or, more importantly, REM sleep (Fig. 4b). An expanded 10 s (one epoch) 
view of SW and REM sleep EEG-2 waveforms shows that the majority of frequencies that 
comprise SW sleep fall into the 1–4 Hz frequency range. The SW sleep epoch also shows a 
significantly larger EEG-2 amplitude than either wake or REM sleep. By contrast, REM 
sleep exhibits a predominance of 5–8 Hz activity and an amplitude that is visually lower 
than SW sleep.
2.7. Determination of sleep and wake episodes for the purpose of L-glutamate analysis
Wake episodes were globally classified as periods of at least 15 min in length where no more 
than five continuous minutes of SW sleep was present. A wake episode was considered 
terminated when five or more continuous minutes of sleep (SW or REM) were observed. 
Sleep episodes were globally classified as at least 15 min of continuous sleep with both SW 
and REM sleep epochs contributing as part of the same sleep episode. A sleep episode was 
considered terminated when five or more continuous minutes of wake activity were 
observed. REM sleep periods longer than 1 min were disregarded at the end of sleep 
episode. Based on these criteria, the average episode lengths were 32.3 min (wake) and 60.1 
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min (sleep), consistent with the “lights-on” period demonstrating enhanced periods of SW 
and REM sleep.
Biosensor measurements were determined by averaging L-glutamate biosensor readings 
during the first 5 min (baseline value) and the last 5 min (terminal value) of each episode. 
The change during a scored episode was recorded as the difference between the baseline and 
terminal values. Due to the shortened nature of REM episodes, a slightly different method 
was employed. Characterizing REM sleep periods within a sleep episode presents a special 
problem because REM periods have durations of less than 3 min. For REM sleep periods 
lasting longer than 1 min, a baseline was established by averaging L-glutamate 
concentrations for the minute immediately prior to the onset of the REM sleep episode. The 
baseline was then subtracted from the L-glutamate concentration during each epoch of the 
REM sleep episode.
3. Results and discussion
This study presents the first concurrent measurements of EEG and EMG activity along with 
simultaneous real-time biosensor recordings in the pre-frontal cortex (PFC) of a mouse. This 
technique provides an unprecedented window into the neurochemistry associated with the 
sleeping brain. The key finding of this study is the consistent fluctuation of L-glutamate 
levels (Fig. 5) in the PFC of a mouse during sleep/wake cycles. Gross correlations between 
all six animals are readily apparent. When scored episodes are aggregated, rising L-
glutamate levels are noted during extended (>15 min) waking periods. By contrast, long 
periods of sleep (>15 min of combined SW and REM sleep) demonstrate an overall decline 
in brain ECF L-glutamate concentration (Fig. 6). The observed L-glutamate levels show a 
statistically significant increase of 0.86 ± 0.26 μM (p < 0.05) over 37 wake episodes 
recorded from all mice (n = 6). Over the course of 49 measured sleep periods longer than 15 
min, L-glutamate concentrations decline by a similar amount (0.88 ± 0.37 μM, p < 0.08). 
Interestingly, sleep and waking episodes <15 min lack a consistently recognizable pattern. 
Despite the recognized importance of L-glutamate as the major excitatory neurotransmitter 
in the brain, changes in L-glutamate concentrations do not occur without concomitant 
changes in brain metabolism directly related to energy use [25]. The simultaneous 
measurement of multiple brain analytes in conjunction with electrophysiological activity 
hold the promise to further unravel these complex and highly intertwined relationships.
Unlike SW sleep, REM sleep demonstrates very different brain wave patterns and is 
generally believed to reflect a period of increased cortical activity distinct from that 
observed during SW sleep. Not surprisingly, a different temporal L-glutamate pattern is 
clearly seen during REM sleep. As shown in Fig. 7, the analysis of 163 individual REM 
sleep episodes greater than one min in length across all mice (n = 6) demonstrates a 
significant rise in L-glutamate levels as compared to the 1 min preceding REM sleep onset 
(RM-ANOVA, DF = 20, F = 6.458, p < 0.001). The observed rapid changes in L-glutamate 
concentration during REM sleep last only between 1 and 3 min. Visualization of this REM 
sleep related L-glutamate concentration change has only recently been possible through the 
use of biosensors employing a rapid (1 Hz) sampling rate. One study [10] employing 1 min 
microdialysis sampling from the orbitofrontal cortex of rats reported REM sleep related L-
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glutamate increases. However, microdialysis studies employing lower sampling frequencies 
(on the order of minutes) likely missed this phenomenon. Unlike the Lopez-Rodriguez 
report [10], the use of biosensors with the characteristics described in the present report 
allow for the direct visualization of discrete events during REM sleep episodes with a 1 s 
temporal resolution [16a] that is currently unattainable by routine microdialysis.
Very similar temporal changes in L-glutamate levels during REM sleep have been reported 
in biosensor studies in rats [5,6]. Our findings in mice support the hypothesis that these 
changes in L-glutamate levels are not an isolated phenomenon of a particular rodent model 
but may reflect a fundamental mechanism underlying REM sleep. Following release, L-
glutamate is rapidly cleared from the synaptic cleft [20]. Increasing L-glutamate 
concentration as measured by the biosensor indicates an increase in L-glutamate release, 
lowered L-glutamate uptake or a combination of these two factors. Other researchers have 
noted rapid rises in L-glutamate concentration during REM sleep [6,10] and active waking 
episodes [5]. L-Glutamate uptake has been shown to be inhibited by the infusion of L-
glutamate via a microdialysis probe [21] and Kullmann et al. [22] have demonstrated that 
released extracellular L-glutamate can spill-over and occupy neighboring synapses, thus 
eliciting further L-glutamate release. Taken together, these findings suggest that extracellular 
L-glutamate concentrations are continually rising during REM sleep while L-glutamate 
uptake is limited or hindered. The neurotoxic nature of exogenous extracellular L-glutamate 
is well established as a mechanism of cell death [23] and it may be that REM sleep periods 
in rodents are limited to short durations to prevent excessive extracellular L-glutamate build-
up as a neuroprotective measure.
4. Conclusions
L-Glutamate is the most abundant excitatory neurotransmitter in the mammalian CNS, 
occupying 90% of all cortical synapses [24]. It should not be surprising that glutamatergic 
transmission represents most of the energy expenditure in the brain [25]. Astrocytes respond 
to L-glutamate release by a cascade of events designed to rapidly increase the available pool 
of energy substrates. Exogenous application of L-glutamate to astrocytes has been 
demonstrated to induce a rapid and reversible increase in glucose transport [26] caused by 
Na+ influx occurring concurrently with astrocytic L-glutamate uptake [27]. The Na+ rise 
induces activation of Na+/K+ ATPase resulting in the glycolytic processing of glucose to 
lactate [28]. Thus, it may be possible to relate extracellular L-glutamate levels as a 
byproduct of glutamatergic synaptic activity. This may further be postulated to act as a proxy 
for determination of local neuronal and astrocytic metabolism [29].
The fluctuations in L-glutamate levels in the PFC during sleep and wake episodes are 
strikingly parallel to those previously reported in the PFC of rats [6]. These results in both 
mice and rats suggest that L-glutamate may be fulfilling similar roles during sleep and 
waking across species. Such a relationship hints at the presence of a modulatory role 
between L-glutamate levels and sleep, the nature of which remains to be fully described. The 
approach described herein can also be extended to other regions of the brain which are 
hypothesized to play a role in sleep. This study highlights the importance of obtaining 
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simultaneous measurements of neurotransmitter levels in conjunction with sleep markers to 
help elucidate the underlying physiological and ultimately the genetic components of sleep.
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Diagrammatic representation of the EEG–EMG-biosensor surgery protocol carried out in 
this study. For this series, the active component in the diagram is illustrated in blue. Fig. 1a – 
depiction of the mouse skull after the skin was been retracted and connective tissue was 
removed revealing bregma, the traditional point of origin for stereotaxic coordinates. Fig. 1b 
– depiction of the three screws used as EEG recording electrodes. Screws for EEG-1 and 
EEG-2 were placed at A/P: −3.0 mm, M/L +1.5 mm and A/P: −1.0 mm, M/L +1.5 mm, 
respectively, while the EEG COMMON screw was located at A/P: −3.0 mm, M/L −1.5 mm. 
Fig. 1c – stereotaxic (measured) placement of a guide cannula at A/P: +1.94 mm, M/L −1.50 
mm, D/V −0.5 mm. Fig. 1d – all items were secured in place with dental acrylic resin (blue). 
Fig. 1e – the connector wires for the three EEG electrodes were separately routed up through 
the dental acrylic resin and then soldered to the pre-fabricated headmount while Pt–Ir EMG 
electrodes (pre-connected to the headmount) are inserted in the nuchal (neck) muscle tissue. 
Fig. 1f – additional dental acrylic resin was added to the headmount and guide cannula to 
secure the entire assembly to the skull. (For interpretation of the references to colour in this 
figure legend, the reader is referred to the web version of this article.)
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A working schematic of the L-glutamate biosensor, including biosensor dimensions. L-
glutamate, in the presence of water and oxygen, is converted (Box 1) into H2O2, NH3 and 
oxoglutaric acid by L-glutamate oxidase (EC 1.4.3.11). The enzymatically-produced H2O2 
diffuses through the selective membrane (Box 2) to the Pt–Ir surface where it is oxidized at a 
potential of 0.6 V vs. Ag/AgCl (Box 3). L-Ascorbate and other electroactive interferents are 
excluded from the Pt–Ir surface by two mechanisms: (1) L-ascorbate oxidase (EC 1.10.3.3), 
in the presence of oxygen, actively removes L-ascorbate (Box 4) by conversion to 
dehydroascorbate and water (neither of which are electroactive at 0.6 V vs. Ag/AgCl), and 
(2) remaining L-ascorbate (Box 5) and other endogenous electroactive interferents are 
further excluded by an inner-selective membrane. While it is not possible to eliminate 100% 
of the electroactive interferents (Box 6), the inner-membrane and active removal of L-
ascorbate effectively limit the amount of interferent that reaches the electrode surface such 
that any changes in the local concentration are insignificant and do not contribute to the 
observed current.
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A representative in vitro L-glutamate biosensor pre-calibration titration graph. The biosensor 
was placed in a jacketed beaker previously charged with 20 ml of 100 mM PBS at ambient 
temperature. Stepwise titration of 10 μM L-glutamate (indicated by blue arrows) was added 
to the rapidly stirred PBS solution. Typically, the effectiveness of the L-ascorbate oxidase 
and interference membranes was assessed via a single 250 μM injection of L-ascorbic acid 
(red arrow). The changes in current as a function of L-glutamate concentration followed a 
linear pattern over a range up to 40 μM (inset graphic). The rejection ratio of L-ascorbic acid 
of this representative biosensor prior to implantation is over 150:1 (manufacturer 
specification) and is improved over the 50:1 reported elsewhere.6 (For interpretation of the 
references to colour in this figure legend, the reader is referred to the web version of this 
article.)
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Representative waveforms for each of the three stages of mouse sleep. Wake epochs are 
characterized by high amplitude EMG activity coupled with high frequency (>12 Hz) low 
amplitude EEG activity. SW sleep epochs are characterized by high amplitude (>100 μV), 
low frequency (<5 Hz) EEG activity, paired with a low amplitude EMG trace. REM sleep 
epochs are characterized by an abundance of 5–8 Hz frequencies (theta) in the EEG traces, 
whose amplitudes are <100 μV, and are coupled with a tonic EMG signal. Scoring of 
discrete epochs has historically been accomplished by visual recognition of these frequency 
and amplitude changes by a trained human scorer. Individual epochs are joined together to 
constitute episodes of wake, SW sleep and REM sleep. While wake and SW sleep episodes 
can be >15 min in length, REM sleep episodes are typically less than 3 min in duration.
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Expanded view of a 10 s. SW and REM sleep EEG epoch. SW sleep epochs are visually 
determined to contain a majority of 1–4 Hz waveform activity and a significantly larger 
amplitude component than either wake or REM sleep epochs. By contrast, REM sleep 
epochs are visually inspected for a predominance of 5–8 Hz activity and an amplitude that 
visually corresponds to that of wake epochs.
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Changes in L-glutamate concentration measured concurrently with sleep state. Graphs 
represent three of the six mice used in this study and reflect the composite EEG/EMG/L-
glutamate concentrations measured over a 12 h time period during lights-on. Individual 
points represent 10 s epochs with colour coding to indicate the scored sleep/wake state (Red 
= wake, Blue = SW sleep, Green = REM sleep). The relative changes in L-glutamate 
concentration on the y-axis are based on individual post-calibration values represented and 
do not denote absolute L-glutamate concentrations. Note that the green periods indicative of 
REM sleep events are shorter in duration than the wake or SW sleep episodes. (For 
interpretation of the references to colour in this figure legend, the reader is referred to the 
web version of this article.)
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Average change in L-glutamate concentration for all wake and sleep episodes greater than 15 
min in duration. Wake episodes were globally classified as periods of at least 15 min in 
length where no more than five continuous minutes of SW sleep was present. A wake 
episode was considered terminated when five or more continuous minutes of sleep (SW or 
REM sleep) was observed. Sleep episodes were globally classified as at least 15 min of 
continuous sleep with both SW and REM sleep epochs contributing as part of the same sleep 
episode. A sleep episode was considered terminated when five or more continuous minutes 
of wake activity was observed. Bars represent SEM ** = p < 0.005.
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Increase in mean L-glutamate level during REM sleep episodes (163 total, n = 6 mice). For 
REM sleep periods lasting longer than 1 min, a baseline was established by averaging L-
glutamate concentrations for the minute immediately prior to the onset of the REM sleep 
episode. The baseline was then subtracted from the L-glutamate concentration during each 
epoch of the REM sleep episode. Bars represent SEM, * = p < 0.05, Fisher’s posthoc 
analysis RM-ANOVA, DF = 20, F = 6.458.
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